

Asymmetric Methallylation of Ketones Catalyzed by a Highly Active Organocatalyst 3,3'-F₂-BINOL

Yongda Zhang, Ning Li, Bo Qu, Shengli Ma, Heewon Lee, Nina C. Gonnella, Joe Gao, Wenjie Li, Zhulin Tan, Johnathan T. Reeves, Jun Wang, Jon C. Lorenz, Guisheng Li, Diana C. Reeves, Ajith Premasiri, Nelu Grinberg, Nizar Haddad, Bruce Z. Lu, Jinhua J. Song, Chris H. Senanayake*

Chemical Development, Boehringer-Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877

E-mail: yongda.zhang@boehringer-ingelheim.com

Supporting Information

Table of Contents


General-----	SI-2
Synthesis of (<i>S</i>)-3,3'-difluoro-1,1'-binaphthyl-2,2'-diol 7-----	SI-3
Synthesis of 5,5-dimethyl-2-(2-methylallyl)-1,3,2-dioxaborinane 4 -----	SI-4
Catalyst screen results-----	SI-5
Allylation of 11a catalyzed by 3,3'-Br ₂ -BINOL and 3,3'-F ₂ -BINOL-----	SI-6
General procedure for the asymmetric methallylation of ketones-----	SI-6
Synthesis of enantioenriched 1-----	SI-14
¹ H and ¹³ C NMR Spectra for all new compounds-----	SI-18
Chiral HPLC traces for methallylation-----	SI-44
X-Ray crystallographic data for compound 7-----	SI-63

General Methods.

All reactions were carried out under an atmosphere of argon or nitrogen in dry glassware with magnetic stirring. Commercially available *n*-BuLi, MOMCl, THF, NFSI (N-fluorobenzenesulfonimide), anhydrous *t*-BuOH and *t*-AmOH were received and used without any further purification. Ketones **11j**,¹ **11k**,¹ **11p**² were synthesized according to literature procedure. Column chromatography was performed on silica gel 60 (230-400 mesh). Thin layer chromatography was performed on 0.25 mm silica gel 60-F plates. Visualization was accomplished with UV light, KMnO₄, aqueous ceric ammonium molybdate, or bromocresol green dips followed by heating. The stereochemistry of methallylation products were assigned by comparison with optical rotation of known compounds such as **12o**.

¹H NMR and spectra were recorded on a 400 MHz spectrometer at ambient temperature. Data are reported as follows: chemical shift in parts per million (δ , ppm) from an internal standard [tetramethylsilane (TMS) or deuterated chloroform (CDCl₃)], multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), integration, and coupling constant (Hz). ¹³C NMR and spectra were recorded on a 400 MHz spectrometer at ambient temperature. Chemical shifts are reported in ppm from CDCl₃ taken as 77.0 ppm. Melting points are uncorrected. Optical rotations were measured on an Autopd[®] III automatic polarimeter.

Synthesis of (*S*)-3,3'-difluoro-1,1'-binaphthyl-2,2'-diol **7**³



A dry and clean flask was charged with 60% NaH (10.48 g, 261.94 mmol, 2.5 equiv) under nitrogen followed by addition of 100 mL of THF. After the resulting suspension was cooled to 0 °C, a solution of (*S*)-1,1'-binaphthyl-2,2'-diol **8** (30 g, 104.78 mmol) in 200 mL of THF was added while maintaining the internal temperature below 5 °C. After 1 h, MOMCl (20.25 g, 251.46 mmol, 2.4 equiv) was added while maintaining the internal temperature below 10 °C. After the solution was stirred for 1 h at 0-5 °C, the reaction was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄. Removal of the solvent gave the product as a pale yellow solid, which was slurried in a mixture solvent (5% EtOAc in Hexane) to give 37 g of the product **9** as an off-white solid with 94% yield.


To a dry 500-mL 3-neck flask was charged **9** (10 g, 26.71 mmol) under nitrogen followed by addition of 100 mL of THF via a syringe. After the resulting solution was cooled to -15 °C, a solution of 2.5 M *n*-BuLi (25.64 mL, 64.10 mmol, 2.4 equiv) in hexane was added while maintaining the internal temperature below -10 °C. After complete addition, the mixture was kept at 0 °C for 1 h to give a thick suspension. The suspension was cooled to -70 °C. NFSI (21.03 g, 64.68 mmol, 2.42 equiv) in 100 mL of THF was added while maintaining the internal temperature < -69 °C. After complete addition, the resulting mixture was kept < -69 °C for 30 min. Then the mixture was allowed to warm up to room temperature. Water was added to quench the reaction followed by addition of EtOAc. The combined organic layers were washed with aq. NaHCO₃, water and brine successively, and dried over anhydrous Na₂SO₄. Removal of the solvent under vacuum gave the crude product, which was purified by silica gel chromatography to give the product **10** as a liquid with 91% yield.

To a flask was charged **10** (6.0 g) and Amberlyst[®] ion-exchange resin 15 (6.0 g). After addition of 30 mL of THF and 30 mL of MeOH, the resulting mixture was heated at reflux for 3 h. After the mixture was cooled to room temperature, the solid was removed

by filtration. The crude product on removal of the solvent was purified on silica gel to give the pure product **7** as a white solid with 93% yield and > 99% ee.

$[\alpha]_D^{22} +22.9$ [c 0.66, CHCl_3]; Melting point: 177-179 °C; ^1H NMR (600.02 MHz, $\text{DMSO-}d_6$), δ 9.57 (s, 2H), 7.89(d, J = 8.4 Hz, 2H), 7.85 (d, J = 12 Hz, 2H), 7.33 (t, J = 7.8 Hz, 2H), 7.20 (t, J = 7.8 Hz, 2H), 6.91 (d, J = 8.4 Hz, 2H); ^{13}C -NMR (150.92 MHz, $\text{DMSO-}d_6$) δ , 152.1, 143.1, 130.6, 127.6, 127.4, 125.5, 124.2, 123.8, 118.0, 111.7; ^{19}F NMR (CDCl_3), δ -135.1 (m, 1F). HRMS (ES pos.): m/z calcd for $\text{C}_{20}\text{H}_{13}\text{F}_2\text{O}_2^+$ ($\text{M} + \text{H}^+$): 323.0878, found: 323.0871; Chiral HPLC conditions: Chiralpak OD-H, 4.6 x 250 mm; 75:25 heptane/2-propanol, 1.2 mL/min, 220 nm, (*R*)-**7**, t = 5.89 min, (*S*)-**7**, t = 8.59 min.

Synthesis of 5,5-Dimethyl-2-(2-methylallyl)-1,3,2-dioxaborinane **4**



To a dry flask was charged Mg turnings (12.0 g, 497 mmol) and THF (350 mL) under argon followed by addition of 1.2 M DIBAL-H in heptane (8.28 mL, 0.03 equiv). The solution was left for 1 h and gradually became grey. 3-chloro-2-methylprop-1-ene (30 g, 331 mmol) was added to the flask while maintaining the temperature between 20-25 °C. After the complete addition, the mixture was stirred for 2 h at that temperature. The solution was titrated with bi-pyridine as indicator.⁴ The concentration is about 0.62 M.


To a dry flask was charged the Grignard reagent (248 mmol, 400 mL) prepared above and MTBE (200 mL) under nitrogen. After the mixture was cooled to -60 °C (dry-ice bath), B(OMe)_3 (25.8 g, 248 mmol, 1 equiv) was added while maintaining the internal temperature below -60 °C. The resulting solution was stirred at -50 to -60 °C for 30 min, and then slowly warm to 0 °C over 30 min. AcCl (17.5 g, 223.2 mmol, 0.9 equiv) was charged while controlling the temperature below 5 °C. After that, the reaction mixture was allowed to warm to room temperature and then 3,3-dimethyl-propane-1,3-diol (23.0 g, 223 mmol, 0.9 equiv) was charged into the flask in one portion. The resulting reaction mixture was stirred at 23 °C overnight. Dioxane (32.78 g, 372 mmol, 1.5 equiv) was added to the mixture. After 2 h, the solid was filtered off through a Celite pad, which was rinsed with MTBE (200 mL). The residue on removal of the solvent was diluted with hexane (100 mL). The solid was removed by filtration. The filtrate was concentrated and

purified by passing a short silica gel column with 10% MTBE in hexanes as elute or by distillation under vacuum to give the boronate **4**.

^1H NMR (400 MHz, CDCl_3): δ 4.66 (s, 1H), 4.62 (s, 1H), 3.61 (s, 4H), 1.77 (s, 3H), 1.67 (s, 2H), 0.96 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3): δ 144.1, 109.4, 72.2, 31.6, 24.5, 21.8. HRMS (ES pos.): m/z calcd for $\text{C}_9\text{H}_{18}\text{BO}_2^+$ ($M + \text{H}^+$): 169.1400, found: 169.1371.


Screen results of various substituted BINOLs.

To a dry and clean flask was charged ketone **3** (2 mmol) and substituted BINOL **C1-C16** (0.20 equiv) under N_2 followed by addition of *t*-BuOH (0.30 g, 4.0 mmol, 2 equiv) and **4** (3 mmol, 1.5 equiv) via syringe. Then the mixture was stirred at 23 °C overnight. The er was determined on chiral HPLC. Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm , mobile phase A (acetonitrile), mobile phase B (0.1% HCO_2H in water, adjusted with NH_4OH to pH = 4.0), 52:48 A/B, λ = 220 nm, flow rate: 1.3 mL min^{-1} . The samples for HPLC were diluted with MeOH.



* 3.0 equiv of **4** and 2.0 equiv of *t*-BuOH were used.

Allylation of 11a catalyzed by 3,3'-Br₂-BINOL 5 and 3,3'-F₂-BINOL 7.



General Procedure for the Asymmetric Methallylation of Ketones with 3,3'-F₂-BINOL 7 as the organocatalyst

To a dry and clean flask was charged ketone (2 mmol) and **7** (12.9 mg, 0.04 mmol, 0.05 equiv) under N₂ followed by addition of *t*-AmOH (0.29 g, 4.0 mmol, 2 equiv) and **4** (3 mmol, 1.5 equiv) via syringe. Then the mixture was stirred at the temperature as indicated in the table 2. The mixture was cooled to room temperature if the reaction was run at 40 °C. The reaction mixture was directly purified by flash chromatography (0-5% EtOAc in hexanes) on silica gel to yield the product.

(*R*)-4-Methyl-1,2-diphenylpent-4-en-2-ol 12a

The general procedure was applied to 1,2-diphenylethanone (0.39 g, 2.0 mmol) in the presence of 2 mol % **7**. The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product as an oil (0.49 g, 98 yield, 93:7 er). ¹H NMR (400 MHz, CDCl₃): δ 7.35-7.14 (m, 8H), 6.97-6.95 (m, 2H), 4.82 (s, 1H), 4.67 (s, 1H), 3.16 (d, *J* = 13.4 Hz, 1H), 3.06 (d, *J* = 13.4 Hz, 1H), 2.76 (d, *J* = 13.6 Hz, 1H), 2.57 (d, *J* = 13.6 Hz, 1H), 2.26 (s, 1H), 1.37 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 145.8, 142.3, 136.6, 130.8, 127.8, 126.5, 125.7, 115.7, 75.6, 50.1, 49.9, 24.3. HRMS (ES pos.): *m/z* calcd for C₁₈H₁₉⁺ (M + H⁺ - H₂O): 235.1481, found: 235.1476. Optical Rotation: [α]_D²² +21.2 (c = 1.13, CHCl₃) for an enantiomerically enriched sample of 93:7 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm, mobile phase A (acetonitrile), mobile phase B (0.1% HCO₂H in water, adjusted with NH₄OH to pH = 4.0), 52:48 A/B, λ = 220 nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**12a**, *t*_{major} = 8.57 min; (*S*)-**12a**, *t*_{minor} = 8.06 min.

(R)-1-(3-Methoxyphenyl)-4-methyl-2-phenylpent-4-en-2-ol 12b

The general procedure was applied to 2-(3-methoxyphenyl)-1-phenylethanone (113 mg, 0.5 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (134 mg, 95% yield, 96:4 er). ¹H NMR (400 MHz, CDCl₃): δ 7.37-7.26 (m, 4H), 7.23-7.17 (m, 1H), 7.09 (t, 1H, *J* = 7.9 Hz), 6.73-6.68 (m, 1H), 6.59 (d, 1H, *J* = 7.4 Hz), 6.43 (bs, 1H), 4.82 (bs, 1H), 4.68 (s, 1H), 3.63 (s, 3H), 3.15 (d, 1H, *J* = 13.4 Hz), 3.03 (d, 1H, *J* = 13.4 Hz), 2.76 (d, 1H, *J* = 13.6 Hz), 2.58 (d, 1H, *J* = 13.6 Hz), 2.27 (s, 1H), 1.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.1, 145.8, 142.3, 138.0, 128.7, 127.8, 126.4, 125.7, 123.2, 115.9, 115.7, 112.5, 75.6, 55.0, 50.1, 50.0, 24.3. HRMS (ES pos.): *m/z* calcd for C₁₉H₂₆NO₂ (M + NH₄⁺): 300.1958, found: 300.1954. Optical Rotation: [α]_D²² +21.1 (*c* = 0.77, CHCl₃) for an enantiomerically enriched sample of 96:4 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm; mobile phase A (acetonitrile), mobile phase B (0.1% HCO₂H in water, adjusted with NH₄OH to pH = 4.0), 52:48 A/B, λ = 220 nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**12b**, *t*_{major} = 7.15 min; (*S*)-**12b**, *t*_{minor} = 6.64 min

(R)-2-(2-Methoxyphenyl)-4-methyl-1-phenylpent-4-en-2-ol 12c

The general procedure was applied to 1-(2-methoxyphenyl)-2-phenylethanone (250 mg, 1.1 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (302 mg, 97% yield, 95:5 er). ¹H NMR (400 MHz, CDCl₃): δ 7.24-7.17 (m, 2H), 7.16-7.10 (m, 3H), 6.99-6.94 (m, 2H), 6.88-6.79 (m, 2H), 4.76 (bs, 1H), 4.67 (bs, 1H), 3.88 (s, 3H), 3.45 (d, 1H, *J* = 13.3 Hz), 3.20 (d, 1H, *J* = 13.5 Hz), 3.09 (d, 1H, *J* = 13.3 Hz), 2.86 (s, 1H), 2.46 (d, 1H, *J* = 13.5 Hz), 1.38 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 142.9, 142.8, 134.8, 130.8, 129.3, 128.6, 126.6, 125.3, 125.1, 125.0, 123.6, 115.8, 74.7, 50.5, 30.2, 24.0. HRMS (ES pos.): *m/z* calcd for C₁₉H₂₁O⁺ (M + H⁺ - H₂O): 265.1287, found: 265.1581. Optical Rotation: [α]_D²² +27.1 (*c* = 0.90, CHCl₃) for an enantiomerically enriched sample of 92.5:7.5 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm; mobile phase A (acetonitrile), mobile phase B (0.1% HCO₂H in water, adjusted with NH₄OH to pH =

4.0), 48:52 A/B, $\lambda = 220$ nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**12c**, $t_{\text{major}} = 10.58$ min; (*S*)-**12c**, $t_{\text{minor}} = 11.28$ min.

(*R*)-2-(4-Fluorophenyl)-4-methyl-1-phenylpent-4-en-2-ol 12d

The general procedure was applied to 1-(4-fluorophenyl)-2-phenylethanone (107.1 mg, 0.5 mmol) in the presence of 5 mol % of **7** (8.06 mg, 0.03 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (136 mg, 97% yield, 96:4 er). ¹H NMR (400 MHz, CDCl₃): δ 7.31-7.24 (m, 2H), 7.19-7.14 (m, 3H), 6.99-6.91 (m, 4H), 4.84 (bs, 1H), 4.67 (bs, 1H), 3.12 (d, 1H, $J = 13.4$ Hz), 3.04 (d, 1H, $J = 13.4$ Hz), 2.74 (d, 1H, $J = 13.6$ Hz), 2.57 (d, 1H, $J = 13.6$ Hz), 2.27 (s, 1H), 1.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 162.8, 160.0, 142.1, 141.5, 136.3, 130.7, 127.9, 127.4, 127.3, 126.6, 116.0, 114.6, 114.4, 75.3, 50.2, 50.1, 24.3. HRMS (ES pos.): m/z calcd for C₁₈H₂₃NFO (M + NH₄⁺): 288.1758, found: 288.1749. Optical Rotation: $[\alpha]_{\text{D}}^{22} +22.3$ ($c = 0.785$, CHCl₃) for an enantiomerically enriched sample of 96:4 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm ; mobile phase A (acetonitrile), mobile phase B (0.1% HCO₂H in water, adjusted with NH₄OH to pH = 4.0), 60:40 A/B, $\lambda = 220$ nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**12d**, $t_{\text{major}} = 4.75$ min; (*S*)-**12d**, $t_{\text{minor}} = 4.41$ min.

(*R*)-2-(4-Chlorophenyl)-4-methyl-1-phenylpent-4-en-2-ol 12e

The general procedure was applied to 1-(4-chlorophenyl)-2-phenylethanone (115.3 mg, 0.5 mmol) in the presence of 5 mol % of **7** (8.06 mg, 0.03 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product **12e** (139 mg, 97% yield, 96:4 er). ¹H NMR (400 MHz, CDCl₃): δ 7.28-7.21 (m, 4H), 7.19-7.14 (m, 3H), 6.97-6.91 (m, 2H), 4.83 (bs, 1H), 4.66 (bs, 1H), 3.12 (d, 1H, $J = 13.4$ Hz), 3.03 (d, 1H, $J = 13.4$ Hz), 2.73 (d, 1H, $J = 13.6$ Hz), 2.56 (d, 1H, $J = 13.6$ Hz), 2.26 (s, 1H), 1.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 144.5, 141.9, 136.2, 132.3, 130.7, 128.0, 127.3, 126.6, 116.1, 75.4, 50.1, 50.0, 24.4. HRMS (ES pos.): m/z calcd for C₁₈H₂₃NCIO (M + NH₄⁺): 304.1463, found: 304.1451. Optical Rotation: $[\alpha]_{\text{D}}^{22} +29.5$ ($c = 0.59$, CHCl₃) for an enantiomerically enriched sample of 96:4 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μ m; mobile phase A (acetonitrile), mobile phase B (0.1% HCO₂H in water, adjusted with NH₄OH to pH = 4.0), 60:40 A/B, λ = 220 nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**12e**, t_{major} = 6.03 min; (*S*)-**12e**, t_{minor} = 5.75 min.

(*R*)-2-(4-Bromophenyl)-4-methyl-1-phenylpent-4-en-2-ol 12f

The general procedure was applied to 1-(4-bromophenyl)-2-phenylethanone (137.6 mg, 0.5 mmol) in the presence of 5 mol % of **7** (8.06 mg, 0.03 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (162 mg, 98% yield, 97:3 er). ¹H NMR (400 MHz, CDCl₃): δ 7.42-7.37(m, 2H), 7.23-7.15 (m, 5H), 6.97-6.91 (m, 2H), 4.84 (bs, 1H), 4.67 (s, 1H), 3.12 (d, 1H, J = 13.4 Hz), 3.03 (d, 1H, J = 13.4 Hz), 2.73 (d, 1H, J = 13.7 Hz), 2.56 (d, 1H, J = 13.7 Hz), 2.26 (s, 1H), 1.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 145.0, 141.9, 136.1, 130.9, 130.7, 128.0, 127.6, 126.6, 120.4, 116.1, 75.4, 50.1, 50.0, 24.4. HRMS (ES pos.): m/z calcd for C₁₈H₂₃NBrO (M + NH₄⁺): 348.0958, found: 348.0940. Optical Rotation: $[\alpha]_{\text{D}}^{22}$ +40 (c = 0.80, CHCl₃) for an enantiomerically enriched sample of 97:3 er.

Chiral HPLC conditions: Chiralpak OD-H, 4.6 x 250 mm; 98:2 heptane/*iso*-propanol, 1.0 mL/min; 220 nm; (*R*)-**12f**, t = 16.47 min; (*S*)-**12f**, t = 19.54 min.

(*R*)-2-(4-Methoxyphenyl)-4-methyl-1-(naphthalen-1-yl)pent-4-en-2-ol 12g

The general procedure was applied to 1-(4-methoxyphenyl)-2-(naphthalen-1-yl)ethanone (138 mg, 0.5 mmol) in the presence of 5 mol % of **7** (8.06 mg, 0.03 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (159.6 mg, 96% yield, 93:7 er). ¹H NMR (400 MHz, CDCl₃): δ 8.14-8.06 (m, 1H), 7.84-7.77 (m, 1H), 7.70 (d, 1H, J = 8.1 Hz), 7.48-7.38 (m, 2H), 7.34-7.27 (m, 3H), 7.11 (d, 1H, J = 7.0 Hz), 6.84-6.78 (m, 2H), 4.81 (s, 1H), 4.63 (s, 1H), 3.78 (s, 3H), 3.66 (d, 1H, J = 14.0 Hz), 3.46 (d, 1H, J = 14.0 Hz), 2.83 (d, 1H, J = 13.6 Hz), 2.60 (d, 1H, J = 13.6 Hz), 2.23 (s, 1H), 1.37 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 158.2, 142.5, 138.5, 133.8, 133.5, 133.2, 129.4, 128.5, 127.2, 126.8, 125.6, 125.3, 125.0, 115.8, 113.2, 76.0, 55.2, 49.8, 45.9, 24.4. HRMS (ES pos.): m/z calcd for C₂₃H₂₈NO₂ (M + NH₄⁺): 350.2115, found: 350.2093. Optical Rotation: $[\alpha]_{\text{D}}^{22}$ +37.4 (c = 0.96, CHCl₃) for an enantiomerically enriched sample of 93:7 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μ m; mobile phase A (acetonitrile), mobile phase B (0.1% HCO₂H in water, adjusted with NH₄OH to pH = 4.0), 52:48 A/B, λ = 220 nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**12g**, t_{major} = 26.23 min; (*S*)-**12g**, t_{minor} = 27.77 min.

(*R*)-2-(4-Methoxyphenyl)-4-methyl-1-(naphthalen-2-yl)pent-4-en-2-ol 12h

The general procedure was applied to 1-(4-methoxyphenyl)-2-(naphthalen-2-yl)ethanone (138 mg, 0.5 mmol) in the presence of 5 mol % of **7** (16.73 mg, 0.05 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product **12h** (164 mg, 99% yield, 98:2 er). ¹H NMR (400 MHz, CDCl₃): δ 7.79-7.68 (m, 2H), 7.61 (d, 1H, J = 8.4 Hz), 7.49 (s, 1H), 7.45-7.37 (m, 2H), 7.28-7.22 (m, 2H), 7.06-7.01 (m, 1H), 6.84-6.78 (m, 2H), 4.83(s, 1H), 4.67 (s, 1H), 3.79 (s, 3H), 3.30 (d, 1H, J = 13.4 Hz), 3.19 (d, 1H, J = 13.4 Hz), 2.77 (d, 1H, J = 13.6 Hz), 2.59 (d, 1H, J = 13.6 Hz), 2.29 (s, 1H), 1.40(s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 158.2, 142.5, 137.9, 134.4, 133.2, 132.2, 129.4, 129.3, 127.7, 127.5, 127.1, 126.8, 125.7, 125.4, 115.7, 113.2, 75.5, 55.2, 50.2, 50.1, 24.4. HRMS (ES pos.): m/z calcd for C₂₃H₂₃O (M + H⁺-H₂O): 315.1743, found: 315.1730. Optical Rotation: $[\alpha]_{\text{D}}^{22}$ +80.4 (c = 0.83, CHCl₃) for an enantiomerically enriched sample of 98:2 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μ m; mobile phase A (acetonitrile), mobile phase B (0.1% HCO₂H in water, adjusted with NH₄OH to pH = 4.0), 60:40 A/B, λ = 220 nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**12h**, t_{major} = 10.31 min; (*S*)-**12h**, t_{minor} = 11.33 min.

(*R*)-1-Chloro-3-(4-fluorophenyl)-5-methylhex-5-en-3-ol 12i

The general procedure was applied to 3-chloro-1-(4-fluorophenyl)propan-1-one (96 mg, 0.5 mmol) in the presence of 5 mol % of **7** (8.06 mg, 0.03 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (115 mg, 95% yield, 85:15 er). ¹H NMR (400 MHz, CDCl₃): δ 7.39-7.32 (m, 2H), 7.06-7.00 (m, 2H), 4.94 (bs, 1H), 4.77 (bs, 1H), 3.60-3.52 (m, 1H), 3.18-3.10 (m, 1H), 2.64 (d, 1H, J = 13.3 Hz), 2.54 (d, 1H, J = 13.3 Hz), 2.52 (s, 1H), 2.38-2.24 (m, 2H), 1.32 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 141.5, 140.4, 126.8, 116.8, 115.2, 115.0, 74.2, 51.5, 46.4, 40.0, 24.3. HRMS (ES pos.): m/z calcd for C₁₃H₁₅ClF⁺ (M + H⁺-H₂O):

225.0841, found: 225.0837. Optical Rotation: $[\alpha]_D^{22}$ -56.3 ($c = 0.70$, CHCl_3) for an enantiomerically enriched sample of 85:15 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm ; mobile phase A (acetonitrile), mobile phase B (0.1% HCO_2H in water, adjusted with NH_4OH to pH = 4.0), 52:48 A/B, $\lambda = 220$ nm, flow rate: 1.3 mL min^{-1} . The samples for HPLC were diluted with MeOH. (*R*)-**12i**, $t_{\text{major}} = 5.32$ min; (*S*)-**12i**, $t_{\text{minor}} = 5.63$ min.

(*R*)-4-Methyl-1-phenyl-2-(thiophen-3-yl)pent-4-en-2-ol 12j

The general procedure was applied to 2-phenyl-1-(thiophen-3-yl)ethanone (0.21 g, 1.04 mmol) in the presence of 5 mol % of **7** (16.73 mg, 0.05 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (0.26 g, 98% yield, 96:4 er). ^1H NMR (400 MHz, CDCl_3), δ 7.27-7.25 (m, 1H), 7.20-7.16 (m, 3H), 6.97-6.93 (m, 4H), 4.86 (m, 1H), 4.70 (m, 1H), 3.02 (d, $J = 13.32$ Hz, 1H), 3.03 (d, $J = 13.36$ Hz, 1H), 2.67 (d, $J = 13.44$ Hz, 1H), 2.55 (d, $J = 13.44$ Hz, 1H), 2.33 (s, 1H), 1.44 (s, 3H). ^{13}C -NMR (100 MHz, CDCl_3) δ 148.1, 142.3, 136.5, 130.6, 127.8, 126.5, 126.0, 125.4, 120.6, 115.7, 75.0, 50.2, 49.6, 24.1. HRMS (ES pos.): m/z calcd for $\text{C}_{16}\text{H}_{22}\text{NOS}$ ($\text{M} + \text{NH}_4^+$): 276.1417, found: 276.1416. Optical Rotation: $[\alpha]_D^{22} +1.39$ ($c = 0.79$, CHCl_3) for an enantiomerically enriched sample of 96:4 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm ; mobile phase A (acetonitrile), mobile phase B (0.1% HCO_2H in water, adjusted with NH_4OH to pH = 4.0), 40:60 A/B, $\lambda = 220$ nm, flow rate: 1.3 mL min^{-1} . The samples for HPLC were diluted with MeOH. (*R*)-**12j**, $t_{\text{major}} = 23.36$ min; (*S*)-**12j**, $t_{\text{minor}} = 24.38$ min.

(*R*)-4-Methyl-1-phenyl-2-(thiophen-2-yl)pent-4-en-2-ol 12k

The general procedure was applied to 2-phenyl-1-(thiophen-2-yl)ethanone (0.21 g, 1.04 mmol) in the presence of 5 mol % of **7** (16.73 mg, 0.05 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (0.26 g, 97% yield, 97:3 er). ^1H NMR (400 MHz, CDCl_3), δ 7.26-7.18 (m, 3H), 7.15-7.13 (m, 1H), 7.06-7.03 (m, 2H), 6.92-6.90 (m, 1H), 6.76-6.74 (m, 1H), 4.91 (m, 1H), 4.73 (m, 1H), 3.18 (d, $J = 13.4$ Hz, 1H), 3.10 (d, $J = 13.4$ Hz, 1H), 2.70 (d, $J = 13.5$ Hz, 1H), 2.61 (dd, $J = 0.64, 13.5$ Hz, 1H), 2.58 (s, 1H), 1.50 (s, 3H). ^{13}C -NMR (100 MHz, CDCl_3) δ 151.8, 142.1, 136.2, 130.7, 127.9, 126.7, 126.7, 123.7, 123.1, 116.1,

75.1, 51.1, 50.7, 24.2. HRMS (ES pos.): m/z calcd for $C_{16}H_{22}NOS$ ($M + NH_4^+$): 276.1417, found: 276.1419. Optical Rotation: $[\alpha]_D^{22} +13.5$ ($c = 0.89$, $CHCl_3$) for an enantiomerically enriched sample of 96:4 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm ; mobile phase A (acetonitrile), mobile phase B (0.1% HCO_2H in water, adjusted with NH_4OH to pH = 4.0), 40:60 A/B, $\lambda = 220$ nm, flow rate: 1.3 mL min^{-1} . The samples for HPLC were diluted with MeOH. (*R*)-**12k**, $t_{major} = 24.43$ min; (*S*)-**12k**, $t_{minor} = 26.30$ min.

(*S*)-5-Methyl-1,3-diphenylhex-5-en-3-ol 12l

The general procedure was applied to 1,3-diphenylpropan-1-one (125 mg, 0.59 mmol) in the presence of 5 mol % of **7** (9.58 mg, 0.03 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (154 mg, 97% yield, 91:9 er). 1H NMR (400 MHz, $CDCl_3$) δ 7.46-7.43 (m, 2H), 7.37-7.33 (m, 2H), 7.26-7.21 (m, 3H), 7.15-7.08 (m, 3H), 4.90 (m, 1H), 4.77 (bs, 1H), 2.72-2.56 (m, 3H), 2.42 (s, 1H), 2.30-2.06 (m, 3H), 1.30 (s, 3H). ^{13}C -NMR (100 MHz, $CDCl_3$) δ 145.9, 142.6, 142.4, 128.4, 128.3, 128.2, 126.5, 125.7, 125.4, 116.0, 75.0, 51.5, 45.5, 30.0, 24.3. HRMS (ES pos.): m/z calcd for $C_{19}H_{21}^+$ ($M + H^+ - H_2O$): 249.1638, found: 249.1639. Optical Rotation: $[\alpha]_D^{22} -75.6$ ($c = 0.88$, $CHCl_3$) for an enantiomerically enriched sample of 91:9 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm ; mobile phase A (acetonitrile), mobile phase B (0.1% HCO_2H in water, adjusted with NH_4OH to pH = 4.0), 60:40 A/B, $\lambda = 220$ nm, flow rate: 1.3 mL min^{-1} . The samples for HPLC were diluted with MeOH. (*R*)-**12l**, $t_{minor} = 8.17$ min; (*S*)-**12l**, $t_{major} = 7.36$ min.

(*S*)-2-Methyl-4,7-diphenylhept-1-en-4-ol 12m

The general procedure was applied to 1,4-diphenylbutan-1-one (125 mg, 0.56 mmol) in the presence of 5 mol % of **7** (8.98 mg, 0.03 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (150 mg, 96% yield, 90:10 er). 1H NMR (400 MHz, $CDCl_3$): δ 7.23-7.07 (m, 10 H), 4.86 (s, 1H), 4.72 (s, 1H), 2.63-2.49 (m, 4H), 2.33 (s, 1H), 1.91-1.80 (m, 3H), 1.38-1.29 (m, 1H), 1.27 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 146.1, 142.5, 142.4, 128.4, 128.2, 128.0, 126.4, 125.7, 125.3, 115.9, 75.0, 51.3, 43.1, 36.1, 25.3, 24.3. HRMS (ES pos.): m/z calcd

for $\text{C}_{20}\text{H}_{28}\text{NO}^+$ ($\text{M} + \text{NH}_4^+$): 298.2165, found: 298.2156. Optical Rotation: $[\alpha]_{\text{D}}^{22}$ -44.8 ($c = 0.65$, CHCl_3) for an enantiomerically enriched sample of 90:10 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm ; mobile phase A (acetonitrile), mobile phase B (0.1% HCO_2H in water, adjusted with NH_4OH to pH = 4.0), 60:40 A/B, $\lambda = 220$ nm, flow rate: 1.3 mL min^{-1} . The samples for HPLC were diluted with MeOH. (*R*)-**12m**, $t_{\text{minor}} = 8.34$ min; (*S*)-**12m**, $t_{\text{major}} = 6.83$ min.

(*R*)-1-(Benzyloxy)-4-methyl-2-phenylpent-4-en-2-ol 12n

The general procedure was applied to 2-(benzyloxy)-1-phenylethanone (0.23 g, 1.02 mmol) in the presence of 5 mol % of **7** (6.55 mg, 0.02 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product **12n** (269 mg, 93% yield, 85:15 er). ^1H NMR (400 MHz, CDCl_3), δ 7.44-7.42 (m, 2H), 7.34-7.22 (m, 8H), 4.78 (m, 1H), 4.63 (m, 1H), 4.54 (bs, 2H), 3.65 (d, $J = 9.4$ Hz, 1H), 3.62 (d, $J = 9.3$ Hz, 1H), 2.88 (s, 1H), 2.68 (d, $J = 13.68$ Hz), 2.57 (d, $J = 13.68$ Hz, 1H), 1.46 (s, 3H). ^{13}C -NMR (100 MHz, CDCl_3) δ 144.2, 141.9, 138.0, 128.4, 128.0, 127.8, 127.7, 126.8, 125.5, 115.2, 77.3, 75.5, 73.4, 47.1, 24.3. HRMS (ES pos.): m/z calcd for $\text{C}_{19}\text{H}_{26}\text{NO}_2$ ($\text{M} + \text{NH}_4^+$): 300.1958, found: 300.1959. Optical Rotation: $[\alpha]_{\text{D}}^{22}$ -24.3 ($c = 1.02$, CHCl_3) for an enantiomerically enriched sample of 84:16 er.

Chiral HPLC conditions: Chiralcel OJ-3, 4.6 x 150 mm, 5 μm ; mobile phase A (heptane), mobile phase B (IPA), 92:8 A/B, $\lambda = 220$ nm, flow rate: 1.0 mL min^{-1} . The samples for HPLC were diluted with MeOH. (*R*)-**12n**, $t_{\text{major}} = 6.63$ min; (*S*)-**12n**, $t_{\text{minor}} = 9.53$ min.

(*S*)-4-Methyl-2-phenylpent-4-en-2-ol 12o⁵

The general procedure was applied to acetophenone (60 mg, 0.50 mmol) in the presence of 5 mol % of **7** (0.025 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product **12n** (85 mg, 96% yield, 78:22 er). Optical Rotation: $[\alpha]_{\text{D}}^{22}$ -43.2 ($c = 3.49$, CHCl_3) for an enantiomerically enriched sample of 78:22 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm , mobile phase A (acetonitrile), mobile phase B (0.1% HCO_2H in water, adjusted with NH_4OH to pH =

4.0), 52:48 A/B, $\lambda = 220$ nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**12o**, $t_{\text{minor}} = 3.75$ min; (*S*)-**12o**, $t_{\text{major}} = 4.89$ min.


(*R*)-tert-Butyl 3-hydroxy-5-methyl-3-phenylhex-5-enoate **12p**

The general procedure was applied to tert-butyl 3-oxo-3-phenylpropanoate (0.23 g, 0.98 mmol) in the presence of 5 mol % of **1** (15.82 mg, 0.05 mmol). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product **12p** (275 mg, 95% yield, 78:22 er). ¹H NMR (400 MHz, CDCl₃), δ 7.44-7.42 (m, 2H), 7.32-7.29 (m, 2H), 7.26-7.21 (m, 1H), 4.82 (m, 1H), 4.63 (m, 1H), 4.42 (bs, 1H), 2.89 (d, $J = 11.61$ Hz, 1H), 2.77 (d, $J = 15.52$ Hz, 1H), 2.50 (d, $J = 13.56$ Hz, 1H), 2.45 (d, $J = 13.52$ Hz, 1H), 1.62 (s, 3H), 1.23 (s, 9H). ¹³C-NMR (100 MHz, CDCl₃) δ 172.3, 146.0, 142.0, 127.9, 126.7, 125.3, 115.3, 81.7, 75.3, 51.4, 45.8, 27.8, 24.3. HRMS (ES pos.): m/z calcd for C₃₄H₄₈NaO₆ (2M + Na⁺): 575.3343, found: 575.3352. Optical Rotation: $[\alpha]_{\text{D}}^{22} +11.8$ ($c = 0.89$, CHCl₃) for an enantiomerically enriched sample of 80:20 er.

Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm ; mobile phase A (acetonitrile), mobile phase B (0.1% HCO₂H in water, adjusted with NH₄OH to pH = 4.0), 48:52 A/B, $\lambda = 220$ nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**12p**, $t_{\text{major}} = 7.31$ min; (*S*)-**12p**, $t_{\text{minor}} = 9.10$ min.


Synthesis of enantioenriched (*R*)-tert-butyl 4-(6-(2-methylallyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)piperidine-1-carboxylate **1**

Synthesis of tert-butyl 4-isocyanatopiperidine-1-carboxylate 13



To a flask was charged KHCO₃ (5.75 g; 57.42 mmol) and H₂O (50.00 ml; 10.000 V) followed by addition of CH₂Cl₂ (50.00 ml; 10.000 V) and 4-amino-1-Boc-piperidine (5.00 g; 24.97 mmol). The resulting mixture was cooled to 0 °C. Triphosgene (2.56 g; 8.44 mmol) was charged in one portion. After the mixture was stirred for 1h, the organic layer was separated. The aqueous layer was extracted with CH₂Cl₂ (2 x 30 mL). The combined organic layers were washed successively with water and brine, and dried with

anhydrous Na₂SO₄. After removal of the solvent, the residue was dissolved in hexanes. After the mixture was stirred for 1h, the solid (small amount of urea) was filtered off. The filtrate was concentrated to give the tert-butyl 4-isocyanatopiperidine-1-carboxylate **13** as a liquid, which was used for next step directly.



Synthesis of (R)-tert-butyl 4-(6-(2-methylallyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)piperidine-1-carboxylate 1

To a dry flask was charged (*R*)-1-chloro-5-methyl-3-phenylhex-5-en-3-ol **2** (3.20 g, 13.67 mmol) with 87:13 er, tert-butyl 4-isocyanatopiperidine-1-carboxylate **13** (13.67 mmol) and anhydrous toluene (35 mL). After the mixture was cooled to ~10 °C, LiHMDS (1M in toluene, 14.36 mL) was added while maintaining the internal temperature below 25 °C. After 1h, the mixture was extracted with EtOAc (2 X 100 mL), washed successively with aq. NH₄Cl and water, and dried with anhydrous Na₂SO₄. After removal of the solvent, the residue was stirred in 15 mL of hexanes at rt. After overnight, the white solid was collected and washed with 10 mL of 5:1 hexanes/EtOAc to give the product **1** with 99.4:0.6 er (3.5 g, 62% yield).

¹H NMR (400 MHz, CDCl₃): δ 7.37-7.27 (m, 5H), 4.87 (s, 1H), 4.68 (s, 1H), 4.27-4.07 (m, 3H), 3.08-3.04 (m, 1H), 2.75-2.53 (m, 5H), 2.38-2.35 (m, 1H), 2.6-2.21 (m, 1H), 1.66 (bs, 4H), 1.42 (s, 9H), 1.30-1.24 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 154.5, 152.9, 141.9, 140.5, 128.6, 127.6, 124.8, 116.3, 83.1, 79.6, 53.7, 50.8, 43.1, 36.6, 30.4, 28.4, 28.3, 24.3. HRMS (ES pos.): m/z calcd for C₂₄H₃₅N₂O₄⁺ (M + H⁺ - H₂O): 415.2591, found: 415.2598.

Chiral HPLC conditions: Chiralpak AD-H, 4.6 x 250 mm; 85:15 pentane/*iso*-propanol, 1.0 mL/min; 220 nm; (*S*)-**1**, *t*_{minor} = 5.47 min; (*R*)-**1**, *t*_{major} = 6.01 min.

(R)-4-Methylene-1,2-diphenylhexan-2-ol 16

The general procedure was applied to 1,2-diphenylethanone (0.20, 1.02 mmol) in the presence of 5 mol % of **7** (16.42 mg, 0.05 mmol) and boronate **14** (1.53 mmol, 1.5 equiv).

The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product (251 mg, 93% yield, 95:5 er). ¹H NMR (400 MHz, CDCl₃), δ 7.34-7.24 (m, 4H), 7.21-7.14 (m, 4H), 6.97-6.95 (m, 2H), 4.84 (m, 1H), 4.70 (s, 1H), 3.17 (d, *J* = 13.4 Hz, 1H), 3.06 (d, *J* = 13.7 Hz, 1H), 2.79 (d, *J* = 13.7 Hz, 1H), 2.53 (d, *J* = 13.7 Hz, 1H), 2.30 (s, 1H), 1.60 (q, *J* = 7.2 Hz, 2H), 0.83 (t, *J* = 7.4 Hz, 3H). ¹³C-NMR (100 MHz, CDCl₃) δ 147.8, 146.0, 136.7, 130.8, 127.8, 126.4, 126.4, 125.6, 113.3, 75.5, 49.9, 48.5, 29.9, 12.3. HRMS (ES pos.): *m/z* calcd for C₁₉H₂₆NO (M + NH₄⁺): 284.2009, found: 284.2003. Optical Rotation: [α]_D²² +15.6 (c = 0.90, CHCl₃) for an enantiomerically enriched sample of 95:5 er.

Chiral HPLC conditions: Chiralpak OD-H, 4.6 x 250 mm; 98:2 heptane/*iso*-propanol, 1.0 mL/min; 220 nm; (*R*)-**16**, *t*_{major} = 7.71 min; (*S*)-**16**, *t*_{minor} = 11.45 min.

(*R*)-4-Methylene-1,2-diphenyloctan-2-ol **17**

The general procedure was applied to 1,2-diphenylethanone in the presence of 5 mol % of **7** (16.73 mg, 0.05 mmol) and boronate **15** (1.53 mmol, 1.5 equiv). The crude product was purified by column chromatography on silica gel (hexanes: EtOAc = 5:95) to give the product **17** (294 mg, 95% yield, 93:7 er). ¹H NMR (400 MHz, CDCl₃), δ 7.34-7.25 (m, 4H), 7.21-7.14 (m, 4H), 6.98-6.96 (m, 2H), 4.82 (s, 1H), 4.70 (s, 1H), 3.17 (d, *J* = 13.4 Hz, 1H), 3.06 (d, *J* = 13.3 Hz, 1H), 2.79 (d, *J* = 13.6 Hz, 1H), 2.53 (d, *J* = 13.7 Hz, 1H), 2.32 (s, 1H), 1.51-1.59 (m, 1H), 1.53-1.46 (m, 1H), 1.23-1.07 (m, 4H), 0.77 (t, *J* = 7.2 Hz, 3H). ¹³C-NMR (100 MHz, CDCl₃) δ 146.4, 146.0, 136.7, 130.8, 127.8, 126.4, 126.4, 125.6, 114.5, 75.5, 49.9, 48.1, 36.7, 29.9, 22.3, 13.9. HRMS (ES pos.): *m/z* calcd for C₂₁H₃₀NO (M + NH₄⁺): 312.2322, found: 312.2314. Optical Rotation: [α]_D²² +17.1 (c = 0.55, CHCl₃) for an enantiomerically enriched sample of 93:7 er.



Chiral HPLC conditions: Chiralcel OJ-RH, 4.6 x 150 mm, 5 μm; mobile phase A (acetonitrile), mobile phase B (0.1% HCO₂H in water, adjusted with NH₄OH to pH = 4.0), 60:40 A/B, λ = 220 nm, flow rate: 1.3 mL min⁻¹. The samples for HPLC were diluted with MeOH. (*R*)-**17**, *t*_{major} = 7.09 min; (*S*)-**17**, *t*_{major} = 8.24 min.



References:



1. X. Wu, T-A. Chen, L. Zhu, R. D. Rieke, *Tetrahedron Lett.* **1994**, *35*, 3673.
2. J. A. Turner, W. S. Jacks, *J. Org. Chem.* **1989**, *54*, 4229.



3. No racemization was observed in 1:1 THF:3M HCl after 16 h at 60 °C. However, the er changed from >99:1 to 90.5:9.5 in 2M NaOH after 16 h at 100 °C.
4. T. R. Hoye, A. W. Aspaas, B. M. Eklov, T. D. Ryba. *Org. Lett.* **2005**, 7, 2205.
5. J. G. Kim, E. H. Camp, P. J. Walsh, *Org. Lett.* **2006**, 8, 4413-4416.


(S)-3,3'-Difluoro-1,1'-binaphthyl-2,2'-diol 7













5,5-Dimethyl-2-(2-methylallyl)-1,3,2-dioxaborinane 4



102711-054-H





102711-054-C





(R)-1-Chloro-5-methyl-3-phenylhex-5-en-3-ol 2





(R)-4-Methyl-1,2-diphenylpent-4-en-2-ol 12a





(R)-1-(3-Methoxyphenyl)-4-methyl-2-phenylpent-4-en-2-ol 12b





(R)-2-(2-Methoxyphenyl)-4-methyl-1-phenylpent-4-en-2-ol 12c





(R)-2-(4-Fluorophenyl)-4-methyl-1-phenylpent-4-en-2-ol 12d





(R)-2-(4-Chlorophenyl)-4-methyl-1-phenylpent-4-en-2-ol 12e





(R)-2-(4-Bromophenyl)-4-methyl-1-phenylpent-4-en-2-ol 12f






(R)-2-(4-Methoxyphenyl)-4-methyl-1-(naphthalen-1-yl)pent-4-en-2-ol 12g



(R)-2-(4-Methoxyphenyl)-4-methyl-1-(naphthalen-2-yl)pent-4-en-2-ol 12h




(R)-1-Chloro-3-(4-fluorophenyl)-5-methylhex-5-en-3-ol 12i




(R)-4-Methyl-1-phenyl-2-(thiophen-3-yl)pent-4-en-2-ol 12j

102665-030




102665-030




(R)-4-Methyl-1-phenyl-2-(thiophen-3-yl)pent-4-en-2-ol 12k

102665-038-H




102665-038-C




(S)-5-Methyl-1,3-diphenylhex-5-en-3-ol 12l



102665-009



102665-009




(S)-2-Methyl-4,7-diphenylhept-1-en-4-ol 12m




(R)-1-(Benzyloxy)-4-methyl-2-phenylpent-4-en-2-ol 12n



102665-026



102665-026





(S)-4-Methyl-2-phenylpent-4-en-2-ol 12o




(R)-tert-Butyl 3-hydroxy-5-methyl-3-phenylhex-5-enoate 12p

102665-024




(R)-tert-butyl 4-(6-(2-methylallyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)piperidine-1-carboxylate 1

102813-089




102813-089-C




(R)-4-Methylene-1,2-diphenylhexan-2-ol 16

102615-046-H




102615-046-H




(R)-4-Methylene-1,2-diphenyloctan-2-ol 17


102711-024



102711-024-C13




(R)-4-Methyl-1,2-diphenylpent-4-en-2-ol 12a



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.057	BV	0.2172	414.81424	29.64688	49.2910
2	8.580	VB	0.2353	426.74731	27.76923	50.7090


Totals : 841.56155 57.41611



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.062	BV	0.2102	276.80423	20.41046	6.5591
2	8.568	VB	0.2346	3943.35522	257.55811	93.4409


Totals : 4220.15945 277.96856

(R)-1-(3-Methoxyphenyl)-4-methyl-2-phenylpent-4-en-2-ol 12b



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.656	VV	0.1869	4072.97974	337.28018	50.3854
2	7.171	VV	0.2027	4010.67310	306.36887	49.6146


Totals : 8083.65283 643.64905



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.643	BV	0.1809	135.64973	11.55721	3.8567
2	7.151	VB	0.1977	3381.61890	263.54947	96.1433


Totals : 3517.26863 275.10667

(R)-2-(2-Methoxyphenyl)-4-methyl-1-phenylpent-4-en-2-ol 12c



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.484	BV	0.2760	1394.80823	78.24401	49.6480
2	11.151	VB	0.2960	1414.58472	73.68077	50.3520


Totals : 2809.39294 151.92478



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.582	BV	0.2833	1969.88599	107.75513	92.1333
2	11.276	VB	0.3043	168.19673	8.44598	7.8667


Totals : 2138.08272 116.20111

(R)-2-(4-Fluorophenyl)-4-methyl-1-phenylpent-4-en-2-ol 12d



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.388	BV	0.1201	1629.31494	211.03214	49.5229
2	4.723	VV	0.1294	1660.70715	194.92235	50.4771


Totals : 3290.02209 405.95448



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.413	BV	0.1170	50.69893	6.79719	4.1702
2	4.750	VB	0.1297	1165.04358	139.14168	95.8298


Totals : 1215.74251 145.93887

(R)-2-(4-Chlorophenyl)-4-methyl-1-phenylpent-4-en-2-ol 12e



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.809	BV	0.1544	233.62427	23.82161	48.6751
2	6.095	VB	0.1645	246.34253	22.72545	51.3249


Totals : 479.96680 46.54706



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.754	BV	0.1259	37.21839	4.52992	2.7425
2	6.028	VB	0.1649	1319.85571	123.25403	97.2575


Totals : 1357.07410 127.78395

(R)-2-(4-bromophenyl)-4-methyl-1-phenylpent-4-en-2-ol 12f



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.019	BB	0.4378	603.79785	20.85466	50.2976
2	20.372	BB	0.3719	596.65350	25.04594	49.7024


Totals : 1200.45135 45.90060



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.472	BB	0.4268	9634.00586	348.17361	97.0468
2	19.544	BB	0.3992	293.17133	11.20531	2.9532


Totals : 9927.17719 359.37892

(R)-2-(4-Methoxyphenyl)-4-methyl-1-(naphthalen-1-yl)pent-4-en-2-ol 12g



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	26.326	VV	0.6579	8287.64160	184.54683	49.5631
2	27.840	VB	0.7081	8433.74512	172.57779	50.4369


Totals : 1.67214e4 357.12462



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	26.232	BV	0.6838	1.07003e4	234.72682	93.2776
2	27.773	VV	0.5816	771.15674	15.85055	6.7224


Totals : 1.14715e4 250.57737

(R)-2-(4-methoxyphenyl)-4-methyl-1-(naphthalen-2-yl)pent-4-en-2-ol 12h



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.277	VV	0.3044	8240.25391	420.97717	49.9634
2	11.283	VB	0.3338	8252.31152	382.33133	50.0366


Totals : 1.64926e4 803.30850



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.308	BV	0.3036	1.72128e4	882.19946	97.6047
2	11.333	VB	0.3187	422.42014	19.50048	2.3953


Totals : 1.76352e4 901.69994

(R)-1-Chloro-3-(4-fluorophenyl)-5-methylhex-5-en-3-ol 12i



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.339	BV	0.1416	1052.29944	116.29847	49.1793
2	5.639	VB	0.1534	1087.41907	109.94777	50.8207


Totals : 2139.71851 226.24624



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.317	VV	0.1427	392.72311	42.14299	84.5432
2	5.626	VV	0.1574	71.80025	6.57554	15.4568


Totals : 464.52337 48.71853

(R)-4-methyl-1-phenyl-2-(thiophen-3-yl)pent-4-en-2-ol 12j



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.423	BB	0.4430	2975.52954	104.86835	48.3919
2	24.336	BV	0.6237	1584.33020	38.53163	25.7664
3	25.453	VB	0.6620	1588.95581	36.35072	25.8417


Totals : 6148.81555 179.75069



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	23.359	MF	0.6905	7098.75293	171.33400	95.6714
2	24.381	FM	0.5581	321.17899	9.59143	4.3286


Totals : 7419.93192 180.92543

(R)-4-Methyl-1-phenyl-2-(thiophen-3-yl)pent-4-en-2-ol 12k



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	24.288	BV	0.6258	1001.28320	24.65535	49.4156
2	25.410	VB	0.6621	1024.96594	23.25925	50.5844


Totals : 2026.24915 47.91460



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	24.431	BB	0.6510	4120.61377	99.12616	96.8472
2	26.302	BB	0.5441	134.14339	3.30112	3.1528


Totals : 4254.75716 102.42728

(S)-5-Methyl-1,3-diphenylhex-5-en-3-ol 12l



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.515	BV	0.2152	1614.78674	116.84342	50.1815
2	8.311	VB	0.2364	1603.10864	104.83906	49.8185


Totals : 3217.89539 221.68248



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.362	BB	0.2027	2165.67236	165.50398	90.9961
2	8.173	BB	0.2322	214.28937	14.35128	9.0039


Totals : 2379.96173 179.85526

(S)-2-methyl-4,7-diphenylhept-1-en-4-ol 12m



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.863	BB	0.1928	4886.65625	393.63443	49.7315
2	8.364	BB	0.2395	4939.41992	317.44073	50.2685


Totals : 9826.07617 711.07516



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.831	BB	0.1899	1609.17676	130.46039	90.2623
2	8.341	BB	0.2329	173.60240	11.58259	9.7377


Totals : 1782.77916 142.04298

(R)-1-(Benzyloxy)-4-methyl-2-phenylpent-4-en-2-ol 12n



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.630	MM	0.2315	4288.18701	308.76804	84.7423
2	9.527	MM	0.3362	772.07861	38.27243	15.2577


Totals : 5060.26562 347.04047



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.643	MM	0.2272	4575.40479	335.64401	49.7491
2	9.447	MM	0.3554	4621.55811	216.74353	50.2509


Totals : 9196.96289 552.38754

(S)-4-Methyl-2-phenylpent-4-en-2-ol 12o



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.740	BB	0.1004	600.65021	91.68155	50.2221
2	4.884	BB	0.1305	595.33752	70.51340	49.7779


Totals : 1195.98773 162.19495



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.787	BV	0.1038	651.06793	97.62309	22.0325
2	4.975	VB	0.1372	2303.97070	255.51031	77.9675


Totals : 2955.03864 353.13340

(R)-tert-Butyl 3-hydroxy-5-methyl-3-phenylhex-5-enoate 12p



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.360	BB	0.2033	1896.80212	144.35103	49.9853
2	9.160	BB	0.2586	1897.91858	113.80959	50.0147


Totals : 3794.72070 258.16062



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.306	VB	0.2027	2240.48779	171.14331	77.7966
2	9.103	BB	0.2558	639.44269	38.49627	22.2034


Totals : 2879.93048 209.63958

(R)-tert-butyl 4-(6-(2-methylallyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)piperidine-1-carboxylate 1



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.455	MM	0.1660	1125.76025	112.99730	49.9209
2	6.021	MM	0.1884	1129.32776	99.87939	50.0791


Totals : 2255.08801 212.87669



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.468	MM	0.1582	5.86168	6.17572e-1	0.6366
2	6.006	MM	0.1923	914.86511	79.28283	99.3634


Totals : 920.72680 79.90040

(R)-4-Methylene-1,2-diphenylhexan-2-ol 16



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.233	BB	0.4989	3884.16479	109.21716	49.6043
2	10.934	BB	0.4541	3946.13037	124.38062	50.3957


Totals : 7830.29517 233.59777



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.709	BB	0.2512	2725.96973	153.45779	95.4457
2	11.447	BB	0.3722	130.07387	5.22889	4.5543


Totals : 2856.04359 158.68668

(R)-4-Methylene-1,2-diphenyloctan-2-ol 17



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.113	VB	0.1924	1268.09448	102.46413	49.6507
2	8.254	BB	0.2329	1285.93921	85.75674	50.3493

Totals : 2554.03369 188.22087



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.087	BB	0.1952	2845.49854	225.58667	93.0212
2	8.236	BB	0.2288	213.47958	14.41169	6.9788

Totals : 3058.97812 239.99836

X-Ray Crystallographic Data for Compound 7




Figure 1. ORTEP (50% probability level) diagram of asymmetric unit of 7 expanded to show the full fragments.

Table 1. Crystal data and structure refinement for **7**.

Identification code	3,3'-F ₂ -BINOL	
Empirical formula	C ₂₀ H ₁₂ F ₂ O ₂	
Formula weight	322.30	
Temperature	173(2) K	
Wavelength	0.71073 Å	
Crystal system	Hexagonal	
Space group	P3(2)21	
Unit cell dimensions	a = 10.6787(7) Å	α = 90°.
	b = 10.6787(7) Å	β = 90°.
	c = 23.2221(15) Å	γ = 120°.
Volume	2293.3(3) Å ³	
Z	6	
Density (calculated)	1.400 Mg/m ³	
Absorption coefficient	0.106 mm ⁻¹	
F(000)	996	
Crystal size	0.32 x 0.26 x 0.24 mm ³	
Theta range for data collection	2.20 to 28.80°.	
Index ranges	-14 ≤ h ≤ 14, -14 ≤ k ≤ 14, -30 ≤ l ≤ 31	
Reflections collected	24741	
Independent reflections	3825 [R(int) = 0.0253]	
Completeness to theta = 28.80°	96.9 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.9750 and 0.9668	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	3825 / 0 / 222	
Goodness-of-fit on F ²	1.038	
Final R indices [I > 2σ(I)]	R1 = 0.0347, wR2 = 0.1079	
R indices (all data)	R1 = 0.0391, wR2 = 0.1215	
Absolute structure parameter	0.8(6)	
Largest diff. peak and hole	0.267 and -0.226 e.Å ⁻³	

Table 2. Atomic coordinates ($\times 10^4$) and equivalent isotropic displacement parameters ($\text{\AA}^2 \times 10^3$) for 7. U(eq) is defined as one third of the trace of the orthogonalized U^{ij} tensor.

	x	y	z	U(eq)
F(23)	4952(1)	8248(1)	1064(1)	39(1)
O(22)	6384(1)	6915(1)	856(1)	35(1)
C(21)	4813(1)	5611(1)	55(1)	22(1)
C(24)	3364(2)	7159(1)	286(1)	25(1)
C(29)	3614(1)	5377(2)	-293(1)	24(1)
C(210)	2889(2)	6169(2)	-180(1)	24(1)
C(22)	5251(1)	6593(1)	499(1)	25(1)
C(25)	1725(2)	5950(2)	-536(1)	35(1)
C(26)	1288(2)	4993(2)	-984(1)	48(1)
C(28)	3122(2)	4383(2)	-758(1)	35(1)
C(23)	4491(2)	7335(1)	611(1)	26(1)
C(27)	1988(2)	4196(2)	-1092(1)	48(1)
O(12)	8211(1)	60(1)	742(1)	34(1)
F(13)	9544(1)	2700(1)	338(1)	46(1)
C(18)	11614(1)	1667(2)	2365(1)	28(1)
C(11)	9864(1)	749(1)	1550(1)	21(1)
C(12)	9355(1)	1045(2)	1050(1)	25(1)
C(19)	11070(1)	1896(1)	1841(1)	23(1)
C(14)	11196(2)	3588(2)	1097(1)	31(1)
C(15)	12886(2)	4476(2)	1924(1)	35(1)
C(13)	10064(2)	2473(2)	835(1)	31(1)
C(110)	11731(1)	3332(1)	1620(1)	27(1)
C(17)	12718(2)	2805(2)	2656(1)	35(1)
C(16)	13362(2)	4214(2)	2434(1)	40(1)

Table 3. Bond lengths [Å] and angles [°] for **7**. Symmetry transformations used to generate equivalent atoms: #1 y,x,-z #2 x-y,-y,-z+1/3

F(23)-C(23)	1.3484(14)	C(22)-O(22)-H(22)	107.4(16)
O(22)-C(22)	1.3613(16)	C(22)-C(21)-C(29)	119.42(11)
O(22)-H(22)	0.76(2)	C(22)-C(21)-C(21)#1	119.19(11)
C(21)-C(22)	1.3759(17)	C(29)-C(21)-C(21)#1	121.39(11)
C(21)-C(29)	1.4263(17)	C(23)-C(24)-C(210)	119.47(11)
C(21)-C(21)#1	1.498(2)	C(23)-C(24)-H(24)	120.3
C(24)-C(23)	1.3520(19)	C(210)-C(24)-H(24)	120.3
C(24)-C(210)	1.4172(17)	C(28)-C(29)-C(21)	121.74(11)
C(24)-H(24)	0.9500	C(28)-C(29)-C(210)	118.41(11)
C(29)-C(28)	1.4192(18)	C(21)-C(29)-C(210)	119.84(11)
C(29)-C(210)	1.4275(17)	C(25)-C(210)-C(24)	121.83(12)
C(210)-C(25)	1.4110(17)	C(25)-C(210)-C(29)	119.20(12)
C(22)-C(23)	1.4137(18)	C(24)-C(210)-C(29)	118.97(11)
C(25)-C(26)	1.366(2)	O(22)-C(22)-C(21)	124.74(12)
C(25)-H(25)	0.9500	O(22)-C(22)-C(23)	115.66(11)
C(26)-C(27)	1.407(2)	C(21)-C(22)-C(23)	119.59(11)
C(26)-H(26)	0.9500	C(26)-C(25)-C(210)	120.85(13)
C(28)-C(27)	1.366(2)	C(26)-C(25)-H(25)	119.6
C(28)-H(28)	0.9500	C(210)-C(25)-H(25)	119.6
C(27)-H(27)	0.9500	C(25)-C(26)-C(27)	120.11(14)
O(12)-C(12)	1.3506(16)	C(25)-C(26)-H(26)	119.9
O(12)-H(12)	0.8400	C(27)-C(26)-H(26)	119.9
F(13)-C(13)	1.3536(15)	C(27)-C(28)-C(29)	120.67(13)
C(18)-C(17)	1.376(2)	C(27)-C(28)-H(28)	119.7
C(18)-C(19)	1.4200(17)	C(29)-C(28)-H(28)	119.7
C(18)-H(18)	0.9500	F(23)-C(23)-C(24)	120.96(11)
C(11)-C(12)	1.3844(17)	F(23)-C(23)-C(22)	116.37(11)
C(11)-C(19)	1.4279(17)	C(24)-C(23)-C(22)	122.67(11)
C(11)-C(11)#2	1.488(2)	C(28)-C(27)-C(26)	120.74(14)
C(12)-C(13)	1.4123(19)	C(28)-C(27)-H(27)	119.6
C(19)-C(110)	1.4247(18)	C(26)-C(27)-H(27)	119.6
C(14)-C(13)	1.345(2)	C(12)-O(12)-H(12)	109.5
C(14)-C(110)	1.4264(19)	C(17)-C(18)-C(19)	120.85(14)
C(14)-H(14)	0.9500	C(17)-C(18)-H(18)	119.6
C(15)-C(16)	1.370(2)	C(19)-C(18)-H(18)	119.6
C(15)-C(110)	1.4161(19)	C(12)-C(11)-C(19)	119.36(11)
C(15)-H(15)	0.9500	C(12)-C(11)-C(11)#2	119.29(12)
C(17)-C(16)	1.404(3)	C(19)-C(11)-C(11)#2	121.33(11)
C(17)-H(17)	0.9500	O(12)-C(12)-C(11)	124.90(12)
C(16)-H(16)	0.9500	O(12)-C(12)-C(13)	116.20(12)
		C(11)-C(12)-C(13)	118.90(12)
		C(18)-C(19)-C(110)	117.95(12)
		C(18)-C(19)-C(11)	121.88(12)
		C(110)-C(19)-C(11)	120.12(11)
		C(13)-C(14)-C(110)	119.00(12)
		C(13)-C(14)-H(14)	120.5
		C(110)-C(14)-H(14)	120.5
		C(16)-C(15)-C(110)	120.43(14)
		C(16)-C(15)-H(15)	119.8
		C(110)-C(15)-H(15)	119.8
		C(14)-C(13)-F(13)	119.65(12)
		C(14)-C(13)-C(12)	123.72(12)
		F(13)-C(13)-C(12)	116.62(12)
		C(15)-C(110)-C(19)	119.85(12)
		C(15)-C(110)-C(14)	121.29(13)
		C(19)-C(110)-C(14)	118.85(12)
		C(18)-C(17)-C(16)	120.63(14)
		C(18)-C(17)-H(17)	119.7
		C(16)-C(17)-H(17)	119.7
		C(15)-C(16)-C(17)	120.25(13)
		C(15)-C(16)-H(16)	119.9
		C(17)-C(16)-H(16)	119.9

Table 4. Anisotropic displacement parameters ($\text{\AA}^2 \times 10^3$) for **7**. The anisotropic displacement factor exponent takes the form: $-2\pi^2 [h^2 a^{*2} U^{11} + \dots + 2 h k a^* b^* U^{12}]$

	U^{11}	U^{22}	U^{33}	U^{23}	U^{13}	U^{12}
F(23)	46(1)	38(1)	41(1)	-19(1)	-14(1)	28(1)
O(22)	35(1)	35(1)	44(1)	-13(1)	-17(1)	24(1)
C(21)	22(1)	23(1)	26(1)	2(1)	1(1)	15(1)
C(24)	29(1)	27(1)	28(1)	0(1)	2(1)	20(1)
C(29)	25(1)	28(1)	25(1)	-1(1)	-1(1)	17(1)
C(210)	26(1)	32(1)	23(1)	1(1)	0(1)	20(1)
C(22)	24(1)	23(1)	28(1)	0(1)	-4(1)	12(1)
C(25)	36(1)	56(1)	30(1)	-8(1)	-7(1)	36(1)
C(26)	48(1)	82(1)	36(1)	-21(1)	-20(1)	48(1)
C(28)	37(1)	45(1)	36(1)	-15(1)	-9(1)	29(1)
C(23)	29(1)	22(1)	27(1)	-4(1)	-2(1)	14(1)
C(27)	51(1)	70(1)	41(1)	-30(1)	-22(1)	43(1)
O(12)	33(1)	30(1)	35(1)	2(1)	-13(1)	13(1)
F(13)	47(1)	44(1)	43(1)	17(1)	-10(1)	20(1)
C(18)	22(1)	37(1)	26(1)	-3(1)	0(1)	15(1)
C(11)	20(1)	23(1)	21(1)	0(1)	1(1)	12(1)
C(12)	24(1)	28(1)	26(1)	0(1)	-2(1)	14(1)
C(19)	20(1)	27(1)	22(1)	-2(1)	4(1)	12(1)
C(14)	28(1)	25(1)	38(1)	7(1)	8(1)	12(1)
C(15)	29(1)	26(1)	42(1)	-6(1)	6(1)	8(1)
C(13)	32(1)	35(1)	29(1)	8(1)	0(1)	19(1)
C(110)	23(1)	25(1)	29(1)	-1(1)	7(1)	10(1)
C(17)	27(1)	49(1)	28(1)	-8(1)	-3(1)	18(1)
C(16)	27(1)	44(1)	39(1)	-17(1)	-2(1)	11(1)

Table 5. Hydrogen-bond geometry (\AA , $^\circ$).

D - H \cdots A	D - H	H \cdots A	D \cdots A	D - H \cdots A
O(1)-H(1A) \cdots O(2)	0.84	2.19	2.942(2)	149
O(2)-H(2A) \cdots O(1)	0.84	2.11	2.942(2)	171
O(14)-H(14A) \cdots F(2)	0.95	2.49	3.232(3)	134